In the ABACUS trial, the tumor samples with an inflamed phenotype were analyzed for dual CD8+ cells and Granzyme B staining, founding that responding tumors expressed more cells dually stained compared to relapsing ones (87 vs. 30% of dual expression). The gene discussed is GZMB; the disease is neoplasm.